Future Science Group
supplementary figure S2.tif (299.51 kB)

imt-2021-0135: - Supplementary Material: Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer- a meta-analysis

Download (299.51 kB)
posted on 2021-07-15, 11:28 authored by Figshare Future Science GroupFigshare Future Science Group, Ching-Yi Chen, Wang-Chun Chen, Chao-Ming Hung, Yu-Feng Wei

Supplementary Figure S2: Progression-free survival in patients who received etoposide and non-etoposide (carboplatin-paclitaxel) as the standard chemotherapy

Aims: This meta-analysis investigated the clinical benefits of chemo-immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC).
Methods/Results: Seven randomized controlled trials with a total of 2,862 patients were analyzed. Compared with chemotherapy alone, chemo-immunotherapy provided a better progression-free survial (PFS) with a hazard ratio (HR) of 0.81; P<0.00001, and overall survival (OS) (HR, 0.82; P<0.0001). However, the incidence of treatment related adverse effects (TRAEs) was significantly increased. Subgroup analyses showed that a good performance status, cisplatin-based chemotherapy, without brain metastases, and non-Asian populations were associated with greater benefits in OS from chemo-immunotherapy.
Conclusion: Chemo-immunotherapy demonstrated better PFS and OS compared to chemotherapy alone as first-line treatment in ES-SCLC, but additional TRAEs should be closely monitored.


This study was supported by research grants from E-Da Hospital (EDAHP107022).